141.81 USD
-0.9 (-0.63%)
TMDX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. While TMDX has a great health rating, its profitability is only average at the moment. TMDX is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make TMDX suitable for growth investing!
1. Profitability
1.1 Basic Checks
- In the past year TMDX was profitable.
- In the past year TMDX had a positive cash flow from operations.
- In the past 5 years TMDX reported 4 times negative net income.
- In the past 5 years TMDX reported 4 times negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 9.70%, TMDX belongs to the top of the industry, outperforming 93.51% of the companies in the same industry.
- The Return On Equity of TMDX (25.84%) is better than 96.76% of its industry peers.
- With an excellent Return On Invested Capital value of 8.75%, TMDX belongs to the best of the industry, outperforming 88.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.84% | ||
| ROIC | 8.75% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- TMDX's Profit Margin of 16.20% is amongst the best of the industry. TMDX outperforms 92.97% of its industry peers.
- The Operating Margin of TMDX (16.94%) is better than 87.57% of its industry peers.
- TMDX has a Gross Margin of 60.28%. This is in the better half of the industry: TMDX outperforms 61.62% of its industry peers.
- TMDX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
- TMDX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for TMDX has been increased compared to 1 year ago.
- The number of shares outstanding for TMDX has been increased compared to 5 years ago.
- The debt/assets ratio for TMDX has been reduced compared to a year ago.
2.2 Solvency
- TMDX has an Altman-Z score of 5.99. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of TMDX (5.99) is better than 80.54% of its industry peers.
- TMDX has a debt to FCF ratio of 4.24. This is a neutral value as TMDX would need 4.24 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 4.24, TMDX belongs to the top of the industry, outperforming 80.54% of the companies in the same industry.
- TMDX has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
- The Debt to Equity ratio of TMDX (1.43) is worse than 78.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Altman-Z | 5.99 |
ROIC/WACC0.91
WACC9.61%
2.3 Liquidity
- TMDX has a Current Ratio of 7.69. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
- TMDX has a better Current ratio (7.69) than 88.11% of its industry peers.
- TMDX has a Quick Ratio of 7.13. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
- TMDX's Quick ratio of 7.13 is amongst the best of the industry. TMDX outperforms 88.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 162.77% over the past year.
- Looking at the last year, TMDX shows a very strong growth in Revenue. The Revenue has grown by 41.20%.
- The Revenue has been growing by 79.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
3.2 Future
- The Earnings Per Share is expected to grow by 33.25% on average over the next years. This is a very strong growth
- Based on estimates for the next years, TMDX will show a very strong growth in Revenue. The Revenue will grow by 21.23% on average per year.
EPS Next Y163.67%
EPS Next 2Y71.04%
EPS Next 3Y53.35%
EPS Next 5Y33.25%
Revenue Next Year39.67%
Revenue Next 2Y29.73%
Revenue Next 3Y25.56%
Revenue Next 5Y21.23%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 57.41 indicates a quite expensive valuation of TMDX.
- Compared to the rest of the industry, the Price/Earnings ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 68.11% of the companies listed in the same industry.
- TMDX is valuated expensively when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
- With a Price/Forward Earnings ratio of 48.00, TMDX can be considered very expensive at the moment.
- 69.19% of the companies in the same industry are more expensive than TMDX, based on the Price/Forward Earnings ratio.
- TMDX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.04.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 57.41 | ||
| Fwd PE | 48 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, TMDX is valued a bit cheaper than the industry average as 67.57% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, TMDX is valued a bit cheaper than the industry average as 75.68% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 40.18 | ||
| EV/EBITDA | 40.45 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- TMDX's earnings are expected to grow with 53.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y71.04%
EPS Next 3Y53.35%
5. Dividend
5.1 Amount
- No dividends for TMDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:TMDX (1/14/2026, 2:53:50 PM)
141.81
-0.9 (-0.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-29 2025-10-29/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners111.19%
Inst Owner Change0.01%
Ins Owners2.95%
Ins Owner Change-0.16%
Market Cap4.85B
Revenue(TTM)566.35M
Net Income(TTM)91.77M
Analysts83
Price Target148.84 (4.96%)
Short Float %21.09%
Short Ratio7.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.22%
Min EPS beat(2)84.39%
Max EPS beat(2)100.04%
EPS beat(4)4
Avg EPS beat(4)92.06%
Min EPS beat(4)16.42%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)202.42%
EPS beat(12)10
Avg EPS beat(12)118.6%
EPS beat(16)12
Avg EPS beat(16)90.24%
Revenue beat(2)1
Avg Revenue beat(2)0.71%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)4.34%
Revenue beat(4)3
Avg Revenue beat(4)5.83%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)7.35%
Revenue beat(12)10
Avg Revenue beat(12)12.14%
Revenue beat(16)14
Avg Revenue beat(16)18.13%
PT rev (1m)1.04%
PT rev (3m)-0.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.51%
EPS NY rev (1m)0%
EPS NY rev (3m)10.25%
Revenue NQ rev (1m)-0.12%
Revenue NQ rev (3m)0.3%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 57.41 | ||
| Fwd PE | 48 | ||
| P/S | 8.56 | ||
| P/FCF | 40.18 | ||
| P/OCF | 27.17 | ||
| P/B | 13.64 | ||
| P/tB | 14.18 | ||
| EV/EBITDA | 40.45 |
EPS(TTM)2.47
EY1.74%
EPS(NY)2.95
Fwd EY2.08%
FCF(TTM)3.53
FCFY2.49%
OCF(TTM)5.22
OCFY3.68%
SpS16.57
BVpS10.4
TBVpS10
PEG (NY)0.35
PEG (5Y)N/A
Graham Number24.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.84% | ||
| ROCE | 11.08% | ||
| ROIC | 8.75% | ||
| ROICexc | 18.94% | ||
| ROICexgc | 19.61% | ||
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% | ||
| FCFM | 21.29% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Debt/EBITDA | 4.16 | ||
| Cap/Depr | 224.51% | ||
| Cap/Sales | 10.19% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 146.57% | ||
| Profit Quality | 131.41% | ||
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 | ||
| Altman-Z | 5.99 |
F-Score7
WACC9.61%
ROIC/WACC0.91
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
EPS Next Y163.67%
EPS Next 2Y71.04%
EPS Next 3Y53.35%
EPS Next 5Y33.25%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
Revenue Next Year39.67%
Revenue Next 2Y29.73%
Revenue Next 3Y25.56%
Revenue Next 5Y21.23%
EBIT growth 1Y205.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year317.92%
EBIT Next 3Y87.46%
EBIT Next 5Y68.49%
FCF growth 1Y187.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y802.91%
OCF growth 3YN/A
OCF growth 5YN/A
TRANSMEDICS GROUP INC / TMDX FAQ
Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to TMDX.
Can you provide the valuation status for TRANSMEDICS GROUP INC?
ChartMill assigns a valuation rating of 5 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.
How profitable is TRANSMEDICS GROUP INC (TMDX) stock?
TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.
How financially healthy is TRANSMEDICS GROUP INC?
The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 7 / 10.